Bausch Health Ireland, Targeted Rifaximin GI Delivery Patent
Summary
USPTO granted patent US12611378B2 to Bausch Health Ireland Limited on April 28, 2026, covering GI-specific rifaximin release compositions for targeted delivery to portions of the gastrointestinal tract. The patent, filed June 25, 2021, contains 6 claims and names five inventors. The compositions are formulated to treat diseases and disorders via targeted rifaximin delivery.
“Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
USPTO issued patent US12611378B2 to Bausch Health Ireland Limited covering targeted rifaximin compositions for gastrointestinal delivery. The compositions enable delivery to one or more portions of the GI tract. The patent names five inventors and contains 6 claims under CPC classifications including A61K 9/0056, A61K 47/10, and various A61P therapeutic categories.
For pharmaceutical companies and drug manufacturers developing rifaximin-based therapies or targeted GI delivery systems, this patent establishes intellectual property protection that may constrain freedom to operate in this formulation space. Competitors pursuing similar targeted rifaximin delivery compositions should conduct clearance analyses and consider licensing discussions with Bausch Health Ireland Limited.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Targeted release rifaximin compositions
Grant US12611378B2 Kind: B2 Apr 28, 2026
Assignee
Bausch Health Ireland Limited
Inventors
Jacob Cole, Brian R. Rohrs, Daniel J. Stein, Robert J. Israel, Ezra R. Lowe
Abstract
Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.
CPC Classifications
A61K 9/0056 A61K 47/10 A61K 47/32 A61K 47/38 A61K 9/5026 A61K 9/5078 A61K 9/5084 A61K 9/1676 A61P 7/00 A61P 7/04 A61P 1/00 A61P 7/06 A61P 9/10 A61P 25/16 A61P 25/28 A61P 35/02
Filing Date
2021-06-25
Application No.
18012362
Claims
6
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.